Related Experiment Video
Updated: Mar 6, 2026

Visualizing and Quantifying Pharmaceutical Compounds within Skin using Coherent Raman Scattering Imaging
Published on: November 24, 2021
Topical safety and vasoconstrictive assay-based bioequivalence of a new reformulated mometasone cream
Rajesh Krishna1, Ann Horowitz1, Patrick Larson1
1a Merck Research Laboratories, Merck & Co, Inc , Kenilworth , NJ , USA.
Objectives:
A new improved mometasone furoate (Elocon™) cream with an emulsification system that produces a stable emulsion has been developed. In order to register the product in various markets, it was essential to ensure the cream was topically well tolerated and that it was bioequivalent to the reference product.
Methods:
Phase I clinical studies were performed to assess the local safety and tolerability upon multiple dosing of this new cream as well as to assess the single-dose bioequivalence relative to the marketed product. Bioequivalence was assessed using a vasoconstrictive assay (VCA) after a dose-duration pilot study was completed with the marketed Elocon cream.
Key Findings:
The new mometasone cream and its vehicle were nonirritating in healthy subjects during 21-day patch application (MCII <0.025). The positive control was moderately irritating in the same study. The pivotal VCA study enrolled 162 subjects with 105 detectors included in the analysis of bioequivalence. In the 105 detectors, the ratio (×100%) of AUEC values at ED50 for test vs. standard (90% CI) was 112.91% (105.55, 120.87), within the bioequivalence criteria of (80, 125).
Conclusions:
These studies supported the registration of reformulated mometasone cream in various markets.
More Related Videos
Related Concept Videos
Bioequivalence: Overview
Bioequivalence studies: Biowaivers
Equivalence: In Vitro and In Vivo Bioequivalence
Bioequivalence of Drugs: Drugs with Multiple Indications
Bioequivalence Data: Statistical Interpretation
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

